Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.76 |
| ▸ | NPC1 | O15118 | 5/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.59 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251405 | 0.80 | RXFP1 (0.74) | RAB9ANPC1TP53SMN1; SMN2RXFP1 | |
| SCHEMBL6819428 | 0.79 | RAB9A (0.83) | RAB9ANPC1POLBTP53SMN1; SMN2 | |
| SCHEMBL28870516 | 0.78 | RAB9A (0.71) | RAB9ANPC1POLBTP53SMN1; SMN2 | |
| SCHEMBL3646230 | 0.76 | RXFP1 (0.68) | RAB9ANPC1TP53SMN1; SMN2RXFP1 | |
| SCHEMBL10055020 | 0.76 | NPC1 (0.94) | RAB9ANPC1TP53SMN1; SMN2RXFP1 | |
| SCHEMBL4436642 | 0.76 | KCNK3 (0.77) | RAB9ANPC1POLBTP53SMN1; SMN2 | |
| SCHEMBL3209880 | 0.76 | KDM4E (0.73) | RAB9ANPC1POLBTP53SMN1; SMN2 | |
| SCHEMBL14784718 | 0.76 | RAB9A (0.67) | RAB9ANPC1POLBTP53SMN1; SMN2 | |
| SCHEMBL11590109 | 0.76 | KCNK3 (0.68) | RAB9ANPC1POLBTP53SMN1; SMN2 | |
| SCHEMBL5784671 | 0.76 | MTNR1A (0.64) | RAB9ANPC1POLBTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | RAB9A 733/4885NPC1 869/4885POLB 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.